March 08, 2021

To,
The Manager
BSE Limited
Department of Corporate Services
Phiroze Jeejeebhoy Towers,
Dalal Street, Mumbai – 400 001

To,
The Manager
National Stock Exchange of India Limited
Corporate Communication Department
Exchange Plaza, Bandra Kurla Complex,
Mumbai – 400 050

Scrip Code- 532523
Scrip Symbol- Biocon

Subject: Disclosure pursuant to Regulation 30 of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015 (‘SEBI Listing Regulations’).

Dear Sir/ Madam,

Further to our intimation dated January 7, 2021, in relation to execution of a Share Subscription Agreement (“SSA”) and a Shareholders’ Agreement (“SHA”) between Biocon Limited (the “Company”), Biocon Biologics Limited (“BBL”), existing investors of BBL and Beta Oryx Limited, a wholly owned subsidiary of ADQ (the “Investor”) as applicable, we wish to inform you that the subscription money aggregating to ~Rs. 555 Crores have been received by BBL from the Investor.

Consequently, today the Board of BBL has approved allotment of 1,97,99,305 (One Crore Ninety Seven Lakhs Ninety Nine Thousand Three Hundred Five) equity shares at face value of Rs. 10/- (Indian Rupees Ten only) each at an issue price of Rs. 280.31 (Indian Rupees Two Hundred and Eighty and Paisa Thirty One only) per share including a premium of Rs. 270.31 (Indian Rupees Two Hundred and Seventy and Paisa Thirty One only) per share to the Investor.

This intimation is being made in compliance with Regulation 30, read with Schedule III and other applicable regulations of the SEBI Listing Regulations.

We request you to take this on record and that the same be treated as compliance under the applicable regulation(s).

Thanking you,

Yours faithfully,

For Biocon Limited

Mayank Verma
Company Secretary and Compliance Officer